Literature DB >> 1330346

Tumor-promoting and hepatocarcinogenic effects of 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) in DBA/2NCr and C57BL/6NCr mice and an apparent promoting effect on nasal cavity tumors but not on hepatocellular tumors in F344/NCr rats initiated with N-nitrosodiethylamine.

B A Diwan1, R A Lubet, J M Ward, J A Hrabie, J M Rice.   

Abstract

The tumor-promoting and carcinogenic effects of 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) in the liver and in other organs were quantified and compared to those of phenobarbital (PB) in two inbred strains of mice (C57BL/6NCr, DBA/2NCr) and in F344/NCr rats initiated at 5 weeks of age with N-nitrosodiethylamine (NDEA; 90 mg/kg in mice, 75 mg/kg in rats). Two weeks later animals were placed on a regimen of TCPOBOP once every 2 weeks (administered i.p. or i.g.) or on a diet containing 500 p.p.m. PB as a positive control for the duration of the experiment. Mice were administered TCPOBOP (3.0 mg/kg/dose) for 30 weeks followed by control diet, while rats were given the TCPOBOP regimen (3.0 or 30 mg/kg/dose) for the full 78 weeks of the experiment. TCPOBOP was a complete carcinogen and an extremely potent promoter in both strains of mice, particularly the DBA strain in which NDEA followed by TCPOBOP (i.p.) resulted in death of all the animals within 30 weeks from multiple hepatocellular tumors. TCPOBOP alone induced 100% tumor incidence in DBA mice within 60 weeks. In addition, in both strains of mice, a high proportion of those animals with liver tumors had metastases to the lungs. In contrast, TCPOBOP was ineffective as a liver tumor promoter in F344 rats at even 10 times the dose administered to mice. Interestingly however, TCPOBOP, when given subsequent to NDEA, caused a significant increase in nasal cavity tumors in F344 rats. PB was an effective liver tumor promoter in male DBA mice and male F344 rats, but was relatively ineffective as a promoter in C57 mice. When tumor-promoting activity and induction of cytochrome P450 IIB1 were compared, good agreement between these two parameters was observed. PB was an effective inducer of P450 IIB1 in the rats and in both strains of mice and a potent liver tumor promoter in both DBA mice and F344 rats, whereas TCPOBOP was a potent inducer and tumor promoter in both strains of mice but was negligibly effective as either an inducer or a promoter in F344 rats at even 10-fold higher dosage.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330346     DOI: 10.1093/carcin/13.10.1893

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  11 in total

1.  Excessive hepatomegaly of mice with hepatocyte-targeted elimination of integrin linked kinase following treatment with 1,4-bis [2-(3,5-dichaloropyridyloxy)] benzene.

Authors:  Shashikiran Donthamsetty; Vishakha S Bhave; Corrine S Kliment; William C Bowen; Wendy M Mars; Aaron W Bell; Rachel E Stewart; Anne Orr; Chuanyue Wu; George K Michalopoulos
Journal:  Hepatology       Date:  2011-01-06       Impact factor: 17.425

2.  Early increase in cyclin-D1 expression and accelerated entry of mouse hepatocytes into S phase after administration of the mitogen 1, 4-Bis[2-(3,5-Dichloropyridyloxy)] benzene.

Authors:  G M Ledda-Columbano; M Pibiri; R Loi; A Perra; H Shinozuka; A Columbano
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

3.  Editor's Highlight: Neonatal Activation of the Xenobiotic-Sensors PXR and CAR Results in Acute and Persistent Down-regulation of PPARα-Signaling in Mouse Liver.

Authors:  Cindy Yanfei Li; Sunny Lihua Cheng; Theo K Bammler; Julia Yue Cui
Journal:  Toxicol Sci       Date:  2016-07-13       Impact factor: 4.849

4.  1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene induces substantial hyperplasia in fibrotic mouse liver.

Authors:  Edina Bugyik; Katalin Dezso; Eszter Turányi; Kinga Szurián; Sándor Paku; Peter Nagy
Journal:  Int J Exp Pathol       Date:  2012-01-14       Impact factor: 1.925

5.  Impact of CAR Agonist Ligand TCPOBOP on Mouse Liver Chromatin Accessibility.

Authors:  Nicholas J Lodato; Andy Rampersaud; David J Waxman
Journal:  Toxicol Sci       Date:  2018-07-01       Impact factor: 4.849

6.  The role of stress in the regulation of drug metabolizing enzymes in mice.

Authors:  M Konstandi; M Marselos; A M Radon-Camus; E Johnson; M A Lang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Oct-Dec       Impact factor: 2.569

7.  CCAAT/enhancer-binding protein homologous (CHOP) protein promotes carcinogenesis in the DEN-induced hepatocellular carcinoma model.

Authors:  Viviana Scaiewicz; Avital Nahmias; Raymond T Chung; Tobias Mueller; Boaz Tirosh; Oren Shibolet
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

Review 8.  Animal Models: A Useful Tool to Unveil Metabolic Changes in Hepatocellular Carcinoma.

Authors:  Marina Serra; Amedeo Columbano; Andrea Perra; Marta Anna Kowalik
Journal:  Cancers (Basel)       Date:  2020-11-10       Impact factor: 6.639

9.  A targeted in vivo SILAC approach for quantification of drug metabolism enzymes: regulation by the constitutive androstane receptor.

Authors:  A Kenneth Macleod; Tuo Zang; Zoe Riches; Colin J Henderson; C Roland Wolf; Jeffrey T-J Huang
Journal:  J Proteome Res       Date:  2013-12-12       Impact factor: 4.466

10.  Computational modeling identifies key gene regulatory interactions underlying phenobarbital-mediated tumor promotion.

Authors:  Raphaëlle Luisier; Elif B Unterberger; Jay I Goodman; Michael Schwarz; Jonathan Moggs; Rémi Terranova; Erik van Nimwegen
Journal:  Nucleic Acids Res       Date:  2014-01-23       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.